Summary:
A Randomized, Open-Label, Multiple-Dose Phase II Study to Evaluate Efficacy and Safety of D-0120 Administered in Combination with Allopurinol in Subjects with Gout
Qualified Participants Must:
• Be within the ages of 18-75
•
2 Gout flares in the previous 12 months
•
BMI between 18-40 kg
Qualified Participants May Receive:
For time and travel, recieve up to $1,380.
Study medication.